Immunogenicity and Safety of vYF, a Yellow Fever Vaccine — A Phase 2 Trial

Key Points

This trial aims to compare the immunogenicity and safety of the vYF vaccine to the established YF-VAX.
Conducted a Phase 2 trial
Compared vYF with YF-VAX
Evaluated immunogenicity and safety profiles
vYF showed immunogenicity similar to YF-VAX
Safety profiles were comparable between vYF and YF-VAX

Answers are grounded in this paper and cite their sources.

Phase 2 trial evaluates immunogenicity and safety of vYF in comparison to YF-VAX, suggesting similar profiles.

In this trial, vYF had immunogenicity and safety profiles similar to those of YF-VAX. (Funded by Sanofi; ClinicalTrials.gov number, NCT04942210.).

No takes yet. Share an insight, caveat, or question.

Feroldi et al. (2026) studied this question.

View at Publisher

Ask AI

Bookmark

Share